Oligonucleotide Enhanced Cytotoxicity of Idarubicin for Lymphoma Cells

References

• Bierman P, Vose J., Anderson M. J, Bishop R. J, Kessinger R. MA., Armitage J O. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. Journal of Clinical Oncology 1997; 15: 445–450
   PubMed Web of Science ®Google Scholar
• Bischoff J, Kirn R., Williams H. D, Heise A., Horn C., Muna S., Ng M., Nye L., Sampson A. J, JohannesFattaey A., Mc A., Cormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373–376
   PubMed Web of Science ®Google Scholar
• Bishop M, Iversen R., Bayever L. P, Sharp E., Greiner G. J, Copple C. T, Ruddon L. B, Zon R., Spinolo G., Arneson J., Armitage M., Kessinger O. J. Phase I trial of an antisense oligonucleotide OL(1) p53 in hematologic malignancies. Journal of Clinical Oncology 1997; 14(4)1320–1326
   Web of Science ®Google Scholar
• Bishop M, Jackson R., Tarantolo D. J, Iversen B., Bayever L. P, Joshi E., Sharp S., Pierson G. J, Warkentin L. J, Armitage I. P, Kessinger O. JA. Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1) p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome. Journal of Hematotherapy 1997; 6: 441–446
   PubMedGoogle Scholar
• Bishop M, Warkentin R., Jackson I. P, Bayever D. J, Iverson E., Whalen L. P, Lastovica I. V, Haines K. K, Kessinger A. Antisense oligonucleotide OL(1) p53 for in vitro purging of autologous bone marrow in acute myelogenous leukemia. Progress in Clinical Biological Research 1994; 389: 183–187
   PubMedGoogle Scholar
• Bray S, Schorl D. C, Hall P A. The challenge of p53: Unking biochemistry, biology, and patient management. Stem Cells 1998; 16: 248–260
   PubMed Web of Science ®Google Scholar
• Bunz Dutriaux F., Lengauer A., Waldman C., Zhou T., Brown S., Sedivy P. J, Kinder M. J, Vogelstein W. KB. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282: 1497–1501
   PubMed Web of Science ®Google Scholar
• Cabinillas Hagemeister F., Bodey B. FGP., Freireich F J. An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982; 60: 693–697, JMVP-16
   PubMed Web of Science ®Google Scholar
• Cohen J S, Hogan M E. The new genetic medicines. Scientific American December 1994; 76–82
   PubMed Web of Science ®Google Scholar
• Cotter F E. Antisense therapy for lymphomas. Hematological Oncology 1997; 15: 3–11
   PubMed Web of Science ®Google Scholar
• Cross S, Sanchez M., Morgan A. C, Schimke A. C, Ramel K. M, Idzerda S., Raskind L. RWH., Reid B J. A p53-dependent mouse spindle checkpoint. Science 1995; 267: 1353–1356
   PubMed Web of Science ®Google Scholar
• Dohner Fischer H., Bentz K., Hansen M., Benner K., Cabot A., Diehl G., Schlenk D., Coy R., Stilgenbauer J., Volkmann S., Galle M., Poustka R. P, Hunstein A. W., Lighter P. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85(6)1580–1589
   PubMed Web of Science ®Google Scholar
• Dorr R T, Von Hoff D, Idarubicin D. HCL. Cancer Chemotherapy Handbook, 2^nd. Appleton & Lange, East Norwalk, CT 1994; 551–558
   Google Scholar
• Fisher R, Gaynor I., Dahlberg R. E, Oken S., Grogen M. M, Mize M. T, Glick M. E, Coleman H. JCA, Jr, Miller T P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Fujiwara Grimm T., Mukhopadhyay A. E, Cai T., Owen W. D, Schaub O., Roth J A. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Research 1993; 53: 4129–4133
   PubMed Web of Science ®Google Scholar
• Gaidano Ballerini G., Gong P., Inghirami Z. J, Neri G., Newcomb A., Magrath W. E, Knowles T. I, Dalla M. D, Favera R. p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proceedings of the National Academy of Science USA 1991; 88: 5413
   PubMed Web of Science ®Google Scholar
• Gerwirtz A M, Sokol D L, Ratajczak M Z. Nucleic acid therapeutics: State of the art and future prospects. Blood 1998; 92(3)712–736
   PubMed Web of Science ®Google Scholar
• Gorin N C. Stem cell transplantation in acute leukemia. Bone Marrow Transplantation, R Sackstein, W E Janssen, G J Elfenbein. New York Academy of Sciences, New York, NY 1995; 262–287
   Google Scholar
• Gorin N, Lopez C., Laporte M., Quittet P. J, Lesage P., Lemoine S., Berenson F., Isnard J. R, Grande F., Stachowiak M., Labopin J., Fouillard M., Morel L., Jouet P., Noel P. J, Walter M, Detourmignies P., Aoudjhane L., Bauters M., Najman F. A., Douay L. Preparation and successful engraftment of purified CD34+ bone marrow progenitor cells in patients with non-Hodgkin's lymphoma. Blood 1995; 85(6)1647–1654
   PubMed Web of Science ®Google Scholar
• Greiner T, Moynihan C., Chan J. M, Lytle C. W, Pedersen M. DA., Anderson J R, Weisenburger D D. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996; 87(10)4302–4310
   PubMed Web of Science ®Google Scholar
• Haupt Maya Y., Kazaz R., Oren A. M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296–303
   PubMed Web of Science ®Google Scholar
• Heise Sampson C., JohannesWilliams A., Mc Cormick A., Von F., Hoff D D, Kim D H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Medicine 1997; 3(6)639–645
   PubMed Web of Science ®Google Scholar
• Joshi S, Wu S., Verbik G. A, Algarra J. D, Bishop M. S, Pirruccello R. M, Iversen J. S, Jackson L. PJD, Kessinger M A., Jr, Sharp J G. Oligonucleotides complementary to c-myb messenger RNA inhibit growth and induce apoptosis in human Burkitt lymphoma cells. International Journal of Oncology 1996; 8: 815–820
   PubMed Web of Science ®Google Scholar
• Kastan M, Onyekwere B., Sidransky O., Vogelstein D. B, Craig R W. Participation of p53 protein in the cellular response to DNA damage. Cancer Research 1991; 51: 6304–6311
   PubMed Web of Science ®Google Scholar
• Klimo P., Connors J M. ACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Annals of Internal Medicine 1985; 102: 596–602
   PubMed Web of Science ®Google Scholar
• Kvalheim Sorensen G., Fodstad D., Funderud O., Kiesel S., Dorken S., Nustad B., Jakobsen K., Uglestad E. J, Phil A. Immunomagnetic removal of B-lymphoma cells from human bone marrow: a procedure for clinical use. Bone Marrow Transplantation 1995; 3: 41–41
   Google Scholar
• Livingstone L, White R., Sprouse A., Livanos J., Jacks E. T, Tisty T D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992; 70: 923–935
   PubMed Web of Science ®Google Scholar
• Lowe S, Bodis W., Mc Clatchey S., Remington A., Ruley L., Fisher E. H, Housman E. D, Jacks E. DT. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807–810
   PubMed Web of Science ®Google Scholar
• Nadler L, Takvorian M., Botnick T., Bast L., Finberg C. R, Hellman R., Canello S. GP, Schlossman S F. Anti-B1 monoclonal antibody and complement treatment in autologous bone marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. Lancet 1984; 2: 427–431
   PubMed Web of Science ®Google Scholar
• O'Connor Pjackman M., Jondle J., Bhatia D., Magrath K. I, Kohn K W. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Research 1993; 53: 4776–4780
   PubMed Web of Science ®Google Scholar
• Oren M. FASEB Joumal 1992; 6(13)3169–3176, p53: the ultimate tumor suppressor gene?
   PubMed Web of Science ®Google Scholar
• Phillip Guglielmi T., Hagenbeek C., Somers A., Vander R. Lelie, Bron H., Sonneveld D., Gisselbracht P., Cahn J, Harousseau Y., Coiffier L. J, Biron B., Mandelli P., Chauvin F. F. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New England Journal of Medicine 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Radinsky Fidler R., Price J. I, Esumi E. J, Tsan N., Petty R. CM., Bucana C, Bar D., Eli M. Terminal differentiation and apoptosis in experimental lung metastases of human osteogenic sarcoma cells by wild type p53. Oncogene 1994; 9: 1877–1883
   PubMed Web of Science ®Google Scholar
• Ramqvist Magnusson T., Wang P. K, Szekely Y., Klein L. G, Wiman K G. Wild type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogene 1993; 8: 1495–1500
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Cabanillas A., Hagemeister C. F, Romaguera P., Swan E. J, Velasquez F. W. A phase n trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Annals of Oncology 1995; 6: 609–611
   PubMed Web of Science ®Google Scholar
• Rohatiner A Z, Johnson S., Wprice M.P., Cgarnott A., Amess J. S, Norton A. J, Dorey J. A, Adams E., Whelan K., Matthews S. J, Mac J., Callum P, Oza K., Lister T A. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. Journal of Clinical Oncology 1994; 12: 1177–1185
   PubMed Web of Science ®Google Scholar
• Sharp J G, Chan W C. Detection and relevance of minimal disease in lymphomas. Cancer and Metastasis Reviews 1999; 18: 127–142
   PubMed Web of Science ®Google Scholar
• Sharp J, Kessinger G., Mann A., Crouse S., Armitage A. D, Bierman O. JIP., Weisenburger D D. Outcome of High-Dose Therapy and Autologous Transplantation in Non-Hodgkin's Lymphoma Based on the Presence of Tumor in the Marrow or Infused Hematopoietic Harvest. Journal of Clinical Oncology 1996; 14(1)214–219
   PubMed Web of Science ®Google Scholar
• Shaw Bovey P., Tardy R., Sahli S., Sordat R., Costa B. J. Induction of apoptosis by wild-type p53 in a human colon tumor derived cell line. Proceedings of the National Academy of Science 1992; 89: 4495–4499
   PubMed Web of Science ®Google Scholar
• Shipp M, Harrington A., Klatt P. D, Jochelson M. M, Pinkus S. M, Marshall S. G, Rosenthal L. J, Skarin S. DAT., Cannellos G P. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD of M-BACOD. Annals of Internal Medicine 1986; 104: 757–765
   PubMed Web of Science ®Google Scholar
• Shpall E, Cagnoni J., Gehling J. P, Kami U. LS, Hogan C J. Bone marrow purging. High-Dose Cancer Therapy, Pharmacology, Hematopoietins, Stem Cells, J. O. Armitage, K. Antman. Williams and Wilkins, Baltimore 1995; 289–318
   Google Scholar
• Stein C A, Cheng Y C. Antisense Oligonucleotides as therapeutics: Is the bullet really magical. Science 1993; 261: 1004–1012
   PubMed Web of Science ®Google Scholar
• Uchida He N., Friera D., Reitsma M. A, Sasaki M., Chen D., Tsukamoto B. A. The unexpected G0/G1 cell cycle status of mobilized hematopoietic stem cells from peripheral blood. Blood 1997; 89(2)465–472
   PubMed Web of Science ®Google Scholar
• Velasquez W, Cabanillas S., Salvador F., Mc Laughlin P., Fridrik P., Tucker M., Jagannath S., Hagemeister S., Redman B. F, Swan R. J, Barlogie F. B. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and Dexamethasone (DHAP). Blood 1988; 71: 117–122
   PubMed Web of Science ®Google Scholar
• Yang Eshleman B. JR, Berger N A, Markowitz S D. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clinical Cancer Research 1996; 2: 1649–1657
   PubMed Web of Science ®Google Scholar